Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health


Danaher acquires Abcam. (Credit: National Cancer Institute on Unsplash)

Danaher Corporation announced today it has completed its acquisition of Abcam.

The acquisition of Abcam for $24.00 per share in cash was implemented by way of a Court-sanctioned scheme of arrangement under the UK Companies Act 2006 (the “Scheme”) and the Scheme became effective in accordance with its terms on December 6, 2023.

As a result, Abcam has become an indirect wholly owned subsidiary of Danaher. Trading of Abcam ADSs on Nasdaq has been suspended.

The consideration due to former Abcam shareholders will be settled pursuant to the terms of the Scheme and the consideration due to former Abcam ADS holders will be settled by the Depositary pursuant to the terms of the Deposit Agreement, in each case as further described in the shareholder circular relating to the Scheme, which was published by Abcam on October 5, 2023.

Source: Company Press Release